(lp0
S'Epizyme Earns $6 Million Milestone Payment from GlaxoSmithKline for Initiation ... GlobeNewswire  - Sep 15, 2016 CAMBRIDGE, Mass., Sept. 15, 2016  -- Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics, today announced it has earned a $6 million milestone payment from&nbsp;...'
p1
aS'Epizyme Inc.  Breaks into New 52-Week High on March 16 Session Equities.com - Mar 16, 2017 Shares of Epizyme Inc.  broke into a new 52-week high yesterday, hitting a peak of $17.45. Shares closed at $16.95 after opening at $16.95 for a move of 0%.'
p2
aS'Epizyme President of Research and Chief Scientific Officer, Robert Copeland ... GlobeNewswire  - Mar 9, 2017 CAMBRIDGE, Mass., March 09, 2017  -- Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that President of Research and Chief Scientific Officer, Robert&nbsp;...Epizyme  Reports A Narrower Q4 Loss - Yahoo FinanceEPIZYME, INC.  Files An 8-K Results of Operations and Financial ... - Market Exclusive'
p3
aS'Epizyme Announces Presentation at JP Morgan 35th Annual Healthcare Conference GlobeNewswire  - Jan 3, 2017 CAMBRIDGE, Mass., Jan. 03, 2017  -- Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that Robert Bazemore, chief executive officer of Epizyme, will&nbsp;...'
p4
aS'Epizyme Inc.  Breaks into New 52-Week High on March 15 Session Equities.com - Mar 15, 2017 Shares of Epizyme Inc.  broke into a new 52-week high yesterday, hitting a peak of $17.35. Shares closed at $16.95 after opening at $16.45 for a move of 3.35%.EPS Projection Of Epizyme, Inc.  At $-0.6625 - RealistInvestor.comEpizyme, Inc.  Broker Price Targets For The Coming Week - Fiscal Standard'
p5
aS'Epizyme Inc.  Soars 9.87% on March 10 Equities.com - Mar 10, 2017 Epizyme Inc.  had a good day on the market for Friday March 10 as shares jumped 9.87% to close at $16.70. About 1.01 million shares traded hands on 6,365 trades for the day, compared with an average daily volume of 384,603 shares out of a total&nbsp;...'
p6
aS'Epizyme Establishes Collaboration with Foundation Medicine to Support ... GlobeNewswire  - Sep 21, 2016 CAMBRIDGE, Mass., Sept. 21, 2016  -- Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics, today announced that the Company has entered into a collaboration agreement&nbsp;...'
p7
aS'Epizyme Appoints Pamela Strode as Vice President, Regulatory Affairs and ... GlobeNewswire  - Sep 29, 2016 CAMBRIDGE, Mass., Sept. 29, 2016  -- Epizyme, Inc. , a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that it has appointed Pamela Strode to the&nbsp;...'
p8
aS"Epizyme Provides Update on Execution of Clinical Program and Reports Third ... GlobeNewswire  - Nov 3, 2016 CAMBRIDGE, Mass., Nov. 03, 2016  -- Epizyme, Inc. , a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today recapped recent progress of the Company's clinical-stage programs and&nbsp;..."
p9
aS'The Epizyme Inc  Expected to Earn Q1 2017 Earnings of  Per Share Petro Global News 24 - Mar 17, 2017 Epizyme Inc  - Equities researchers at Leerink Swann issued their Q1 2017 earnings per share  estimates for shares of Epizyme in a note issued to investors on Friday.Epizyme  Reaches $17.00 52-Week High, Raiff Partners Has Trimmed Cbs ... - MoneyMakingArticlesNext Weeks Broker Price Targets For Epizyme, Inc.  - Fiscal Standard'
p10
a.